Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18654234 | 1.00 | BCHE (0.48) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL21650368 | 1.00 | BCHE (0.48) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL20713679 | 1.00 | BCHE (0.48) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL22166492 | 1.00 | BCHE (0.48) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL21886718 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL14413573 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL19944547 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL23348434 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL14208566 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A | |
| SCHEMBL16749107 | 0.96 | BCHE (0.49) | BCHEMEN1USP2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11319338-B2 | Timosaponin compounds | GOLDPORP PHARMA LIMITED (HK) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319338-B2 | Timosaponin compounds | APP, IAPP, BACE1 | BCHE 101/4885MEN1 1058/4885USP2 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.